• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PolyPid Ltd. (Amendment)

    2/10/23 4:05:26 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PYPD alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    POLYPID ltd.

     

    (Name of Issuer)

     

    ordinary shares, NO PAR VALUE

     

    (Title of Class of Securities)

     

    M8001Q118

     

    (CUSIP Number)

     

    December 31, 2022

     

    (Date of Event Which Requires Filing of this Statement)  

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP NO. M8001Q118

     

    (1)

    Names of Reporting Persons.

     

    Gabriel Capital Management Ltd.

    (2) Check the Appropriate Box if a Member of a Group (a) ☐
        (b) ☐
    (3) SEC Use Only
    (4)

    Citizenship or Place of Organization

     

    Israel

    Number of Shares Beneficially Owned By Each Reporting Person With (5) Sole Voting Power 0*
    (6) Shared Voting Power 447,909*
    (7) Sole Dispositive Power 0*
    (8) Shared Dispositive Power 447,909*

    (9) Aggregate Amount Beneficially Owned by Each Reporting Person 447,909*
    (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
    (11) Percent of Class Represented by Amount in Row (9) 2.3%*
    (12) Type of Reporting Person (See Instructions) IA

     

    * See Item 4 for additional information.

     

     

     

     

    Item 1(a). Name Of Issuer
     
     

    PolyPid Ltd. (the “Company”)

     

    Item 1(b). Address of Issuer’s Principal Executive Offices
     
     

    18 Hasivim Street

    Petach Tikva 495376, Israel

     

    Item 2(a). Name of Person Filing
     
     

    This report on Schedule 13G (this “Schedule 13G”), is being filed by Gabriel Capital Management Ltd., a company organized under the laws of Israel (“GCM”).

     

    Item 2(b). Address of Principal Business Office or, if None, Residence
     
     

    The address for GCM is: Jerusalem Technology Park - Malcha Derech Agudat Sport HaPo’el 1, Building 1, Entrance B, 4th Floor, Jerusalem, Israel.

     

    Item 2(c). Citizenship
     
      GCM is organized under the laws of Israel.
       
    Item 2(d). Title of Class of Securities
     
      Ordinary Shares, with no par value (the “Ordinary Shares”).
       
    Item 2(e). CUSIP No.
     
      M8001Q118
       
    Item 3. If This Statement Is Filed Pursuant to Rules 13d-1(b) or 13d-2(b) or (c), Check Whether the Person Filing is a:
     
     

    Not Applicable.

     

     

     

     

    Item 4. Ownership:
         
     

    As reported in the cover pages to this report, the ownership information with respect to GCM is as follows:

     

      (a) Amount Beneficially Owned: 447,909*
      (b) Percent of Class: 2.3%*
      (c) Number of Shares as to which such person has:  
        (i) Sole power to vote or to direct the vote: 0*
        (ii) Shared power to vote or to direct the vote: 447,909*
        (iii) Sole power to dispose or to direct the disposition of: 0*
        (iv) Shared power to dispose or to direct the disposition of: 447,909*

     

    * GCM is the management company to certain affiliated funds (collectively, the “Shavit Funds”). Gabriel Leibler is the sole shareholder of the sole shareholder of GCM. Decisions regarding the voting and disposition of securities held by the Shavit Funds are subject to approval by certain internal investment committees comprising three or more individuals, of which Mr. Leibler is a member. As of December 31, 2022, the Shavit Funds held in the aggregate 447,909 Ordinary Shares. GCM may be deemed to beneficially own such securities held by the Shavit Funds. Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended (the “Act”), Mr. Leibler disclaims beneficial ownership of any such securities held by the Shavit Funds.

     

    In addition, as of December 31, 2022, Mr. Leibler separately held (i) 6,500 Ordinary Shares and (ii) 17,925 Ordinary Shares underlying options at an exercise price of $6.62 per Ordinary Share (including 14,923 Ordinary Shares underlying vested options). Pursuant to Rule 13d-4 under the Act, each of GCM and each of the Shavit Funds disclaims beneficial ownership of any such securities held separately by Mr. Leibler.

     

    The reported beneficial ownership percentage is based upon approximately 19,655,608 Ordinary Shares of the Company, issued and outstanding as of September 30, 2022, based on information reported by the Company in its Form 6-K filed with the Securities and Exchange Commission on November 9, 2022.

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class
     
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person
     
      Not Applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
       
      Not Applicable.
       
    Item 8. Identification and Classification of Members of the Group
     
      Not Applicable.
       
    Item 9. Notice of Dissolution of Group
     
      Not Applicable.
       
    Item 10. Certification
     
      Not Applicable.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 10, 2023  
       
    GABRIEL CAPITAL MANAGEMENT LTD.  
         
    By: /s/ Gabriel Leibler  
    Name:  Gabriel Leibler  
    Title: Sole Director and Shareholder  

     

    Attention: Intentional misstatements or omissions of fact constitute
    Federal criminal violations (See 18 U.S.C. 1001)

     

     

    Get the next $PYPD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PYPD

    DatePrice TargetRatingAnalyst
    6/5/2025$9.00Buy
    Roth Capital
    6/2/2025$11.00Buy
    H.C. Wainwright
    1/28/2025$13.00Buy
    Rodman & Renshaw
    2/11/2022$23.00 → $17.00Strong Buy
    Raymond James
    9/14/2021$14.00Market Outperform
    JMP Securities
    7/30/2021$24.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PYPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

    PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question

    1/28/26 8:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

    PETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. "Brooke's appointment marks an exciting and pivotal moment for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Her global expertise in the surgical market, specifically in infection prevention and advanced surgical solutions, combined with her extensive experience leading corporate strategy and corporate development transactions, will be instrumental in transfor

    12/16/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

    PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New Drug Application ("NDA") meeting minutes from the U.S. Food and Drug Administration ("FDA") supporting the NDA submission of D-PLEX100, the Company's lead product candidate for the prevention of surgical site infections in abdominal colorectal surgeries. The FDA agreed that the Company's existing clinical data package, including results from the Phase 3 SHIELD II trial, appears adequate to support NDA submission and review. The FDA also agreed to a rolling N

    12/3/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    SEC Filings

    View All

    SEC Form 6-K filed by PolyPid Ltd.

    6-K - PolyPid Ltd. (0001611842) (Filer)

    2/4/26 4:05:01 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PolyPid Ltd.

    SCHEDULE 13G/A - PolyPid Ltd. (0001611842) (Subject)

    1/30/26 1:02:52 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PolyPid Ltd.

    6-K - PolyPid Ltd. (0001611842) (Filer)

    12/31/25 4:01:17 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on PolyPid Ltd. with a new price target

    Roth Capital initiated coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $9.00

    6/5/25 7:35:43 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on PolyPid Ltd. with a new price target

    H.C. Wainwright resumed coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $11.00

    6/2/25 8:53:56 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on PolyPid Ltd. with a new price target

    Rodman & Renshaw initiated coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $13.00

    1/28/25 7:16:12 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Leadership Updates

    Live Leadership Updates

    View All

    PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

    PETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. "Brooke's appointment marks an exciting and pivotal moment for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Her global expertise in the surgical market, specifically in infection prevention and advanced surgical solutions, combined with her extensive experience leading corporate strategy and corporate development transactions, will be instrumental in transfor

    12/16/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

    PETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Dr. Nurit Tweezer-Zaks, M.D., M.B.A., as Chief Medical Officer, effective as of August 18, 2025. Dr. Tweezer-Zaks, who has served on PolyPid's Board of Directors (the "Board") since November 2023, will step down from the Board, effective as of August 17, 2025 as she assumes this new executive role. "We are delighted to welcome Dr. Tweezer-Zaks to the executive team at this pivotal time for PolyPid following our positive Phase 3 SHIELD II trial results," said Dikla Czaczkes Aks

    8/12/25 8:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

    PETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive executive business development, clinical, and R&D expertise. She is an experienced sector investor and was a practicing physician for nearly 15 years. "We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board. She has had a distinguished career as a practicing physic

    11/7/23 7:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Financials

    Live finance-specific insights

    View All

    PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

    PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question

    1/28/26 8:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

    Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results Company Continues to Advance Towards Commercial Manufacturing Readiness with Successful Completion of IMOH GMP Inspection Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 202

    11/12/25 7:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

    PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question o

    10/29/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    12/12/24 7:05:07 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    11/29/24 1:20:33 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    10/28/24 4:01:03 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care